Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday…


Previous article4 Ways to Help Destigmatize Psychedelic Therapy in the Black Community
Next articleSilo Wellness Announces Intellectual Property Licensing Agreement of Psilocybin Nasal Spray in Colombia and Brasil